- Home
- ACHC vs RGEN Comparison
ACHC vs RGEN Comparison
Compare ACHC & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHC
- RGEN
- Stock Information
- Founded
- ACHC 2005
- RGEN 1981
- Country
- ACHC United States
- RGEN United States
- Employees
- ACHC N/A
- RGEN N/A
- Industry
- ACHC Medical Specialities
- RGEN Medical/Dental Instruments
- Sector
- ACHC Health Care
- RGEN Health Care
- Exchange
- ACHC Nasdaq
- RGEN Nasdaq
- Market Cap
- ACHC 2.1B
- RGEN 8.0B
- IPO Year
- ACHC N/A
- RGEN N/A
- Fundamental
- Price
- ACHC $22.53
- RGEN $118.15
- Analyst Decision
- ACHC Strong Buy
- RGEN Buy
- Analyst Count
- ACHC 10
- RGEN 12
- Target Price
- ACHC $52.25
- RGEN $172.67
- AVG Volume (30 Days)
- ACHC 2.8M
- RGEN 842.8K
- Earning Date
- ACHC 05-12-2025
- RGEN 04-29-2025
- Dividend Yield
- ACHC N/A
- RGEN N/A
- EPS Growth
- ACHC N/A
- RGEN N/A
- EPS
- ACHC 2.04
- RGEN N/A
- Revenue
- ACHC $3,156,417,000.00
- RGEN $650,429,000.00
- Revenue This Year
- ACHC $7.86
- RGEN $13.93
- Revenue Next Year
- ACHC $8.55
- RGEN $14.35
- P/E Ratio
- ACHC $11.04
- RGEN N/A
- Revenue Growth
- ACHC 5.48
- RGEN 4.88
- 52 Week Low
- ACHC $20.36
- RGEN $102.97
- 52 Week High
- ACHC $82.41
- RGEN $182.52
- Technical
- Relative Strength Index (RSI)
- ACHC 38.50
- RGEN 38.20
- Support Level
- ACHC $24.41
- RGEN $120.11
- Resistance Level
- ACHC $26.25
- RGEN $129.42
- Average True Range (ATR)
- ACHC 1.27
- RGEN 6.02
- MACD
- ACHC -0.02
- RGEN -1.20
- Stochastic Oscillator
- ACHC 3.72
- RGEN 5.96
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.